Blog

Arndt Vogel: 10-year follow up for Pembrolizumab in MSI-H/dMMR Advanced Solid Tumors

Arndt Vogel/X

Jun 4, 2025, 03:51

Arndt Vogel: 10-year follow up for Pembrolizumab in MSI-H/dMMR Advanced Solid Tumors

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:

“10-year follow up for Pembrolizumab in MSI-H/dMMR advanced solid tumors:

KEYNOTE 16

10-yrs OS rate: 46%
Rare progression after 2 years.
We need biomarker to identify (non-) responders.
Great to see 10yr survival data for systemic therapies.”

Arndt Vogel highlighted 10-year overall survival results from the KEYNOTE-16 trial, showing a 46% survival rate with pembrolizumab in MSI-H/dMMR advanced solid tumors. He pointed out the rarity of progression after two years and the ongoing need for biomarkers to predict treatment response.

More posts featuring Arndt Vogel.

Arndt Vogel cancer dMMR 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 fight against cancer Gastroenterology Global fight against cancer Hannover Medical School Hepatology MSI-H OncoDaily Oncology Pembro pembrolizumab solid tumors

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment

15 Posts Not to Miss from the 2nd Day of ASCO 2025